Stock Region Penny Picks
Penny Stock Watchlist Tuesday, December 30, 2025
Penny Stock Watchlist Tuesday, December 30, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
The pre-market action today in our Telegram group was lively, with opportunities unfolding and a mix of familiar and new names making headlines. Here’s a breakdown of the most compelling developments worth watching today.
$EKSO - Ekso Bionics Holdings
$EKSO is attracting significant attention as volume surged following the announcement of a non-binding term sheet to merge with Applied Digital’s cloud computing business. If the deal is completed, the new entity, ChronoScale Corporation, will focus on accelerated computing for AI workloads.
Analysis: This represents a major strategic shift for Ekso, moving from bionic skeletons toward the high-growth AI infrastructure space. Such a pivot signals bold ambition and could transform the company’s prospects. With the market’s affinity for strong AI narratives, this news has ignited a surge in interest and trading activity. The transition to ChronoScale will be a key storyline to track, and in the short term, this announcement acts as a significant catalyst.
$IFRX - InflaRx
An update from $IFRX brings a twist. The company had previously terminated its Phase 3 trial for vilobelimab in treating pyoderma gangrenosum (PG) due to failure to meet the primary endpoint. More recently, post-hoc analyses show a “positive trend” and “signals indicating a potentially consistent treatment effect.”
Analysis: Post-hoc analyses often elicit skepticism from both the market and regulators, appearing as an optimistic reframing of disappointing results. The company plans to meet with the FDA to discuss next steps but acknowledges that future development would require a partner, signaling potential resource constraints. While speculative, any favorable FDA feedback could prompt upside movement.
$PFSA - Profusa
Profusa has restructured its senior secured convertible notes, with the key term now being conversion only above $0.35 per share.
Analysis: This modification is positive for current shareholders, minimizing immediate dilution risk at lower prices and establishing a higher conversion floor. The move reflects confidence from company leadership and supportive backers in reaching or exceeding that price threshold, serving as a technical but bullish development that reduces pressure on the stock.
$SILO - Silo Pharma
Silo Pharma announced the execution of a Letter of Intent with Allucent, a clinical research organization (CRO), to advance Phase 1 clinical development of SPC-15, targeting stress-induced anxiety and PTSD.
Analysis: Partnering with an established CRO like Allucent is an essential milestone for a small pharma entity seeking to progress its pipeline. This step adds credibility and clearly outlines the development path. While not headline-grabbing, such progress supports a longer-term investment thesis.
$AMIX - Autonomix Medical
$AMIX has secured a new European patent for its precision cardiac neuromodulation technology.
Analysis: Securing patents is essential for biotechs and represents a material reduction in risk. European patent protection strengthens Autonomix Medical’s intellectual property position and creates a competitive moat, adding tangible value and anchoring the company’s leadership in the cardiac space.
After-Hours Movers
$ORIS - Oriental Rise Holding Limited
Yesterday after the close, $ORIS signed a non-binding Letter of Intent to acquire Hubei Daguan Tea Industry Group.
Analysis: This acquisition narrative warrants attention, though further details will be paramount in determining the value of the transaction and the target company. Acquisition news often generates short-term volatility and trading opportunities, making this a ticker to watch closely for additional updates.
$ISPC - iSpecimen Inc.
$ISPC announced the pricing of a private placement for approximately $5.5 million after hours.
Analysis: Private placements signal capital needs, and this development points to upcoming dilution, impacting current shareholders. Although necessary for continued operations, this funding approach can exert selling pressure on the stock. Caution is advised until the market absorbs this news and stabilizes.
Disclaimer: This is not a recommendation to buy or sell any securities. All investments carry risk, and you could lose your entire investment. The author of this newsletter may hold positions in the stocks mentioned. Always conduct your own thorough research and due diligence before making any investment decisions.